Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Conditions
Keywords
severe AECOPD, aerosol inhalation and intravenous glucocorticoid
Brief summary
Comparison of aerosol inhalation and intravenous glucocorticoid in the treatment of severe AECOPD-------Multicenter, prospective, randomized, controlled clinical study
Detailed description
This study aims to compare the efficacy and comprehensive benefits of aerosol inhalation and intravenous injection of glucocorticoids in severe AECOPD patients.
Interventions
DRUGaerosol inhalation of glucocorticoids
Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
DRUGintravenous injection of glucocorticoids
Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
Sponsors
Jilin University
Dong Yang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Description for medicine or protocol of treatment in detail: Dosing regimen: 1. Intravenous hormone group: 40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days. 2. Nebulized inhalation group: 2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
(1) Patients with AECOPD requiring hospitalization or emergency treatment (COPD acute attacks combined with respiratory failure were eligible). (2) 18 years of age ≤80 years of age (3) Patients and their families are willing to participate in clinical research and sign informed consent.
Exclusion criteria
1. Combined with tuberculosis. 2. Combined bronchiectasis. 3. complicated with definite infectious diseases. 4. PCT≥0.5ng/ml or CRP≥30mg/L. 5. Serious injury combined with other organ functions 6. Contraindications to other glucocorticoid use. 7. Concomitant bronchial asthma or positive bronchodilation test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relevant indexes after treatment | The day of admission, day one, day two, day three, day five, day seven, day ten | Changes in blood gas indexes (oxygenation index, arterial partial pressure of carbon dioxide, pH value) of patients with respiratory rate, blood pressure, heart rate changes |
Countries
China
Outcome results
None listed